In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
The patient, suffering from calcific severe aortic stenosis—a dangerous narrowing of the heart valve caused by calcium buildup—had run out of standard treatment options
71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
The inspection is now closed, and no regulatory action has been recommended
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
Subscribe To Our Newsletter & Stay Updated
